Document:

Supplemental Indenture

 Exhibit 10.02 

SUPPLEMENTAL INDENTURE 

Supplemental Indenture (this “Supplemental Indenture”), dated as of May 14, 2010, among West Unified Communications
Services, LLC, a Delaware limited liability company (the “Guaranteeing Subsidiary”), West Corporation, a Delaware corporation (the “Issuer”), and The Bank of New York Mellon Trust Company, N.A., as trustee (the
“Trustee”). 
 W I T N E S S E T H 

WHEREAS, the Issuer has heretofore executed and delivered to the Trustee an indenture (the “Indenture”), dated as of
October 24, 2006, providing for the issuance of an unlimited aggregate principal amount of 11% Senior Subordinated Notes due 2016 (the “Notes”); 

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a
supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the
“Guarantee”); 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute
and deliver this Supplemental Indenture; 
 WHEREAS, all things necessary to make this Supplemental Indenture the legal, valid
and binding obligation of the Issuer and the Guaranteeing Subsidiary have been done. 
 NOW THEREFORE, in consideration of the
foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

(1) Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.

 (2) Agreement to Guarantee. The Guaranteeing Subsidiary hereby agrees as follows: 

(a) Along with all Guarantors named in the Indenture, to jointly and severally unconditionally guarantee to each Holder of
a Note authenticated and delivered by the Trustee and to the Trustee and its successors and assigns, irrespective of the validity and enforceability of the Indenture, the Notes or the obligations of the Issuer hereunder or thereunder, that:

 (i) the principal of and interest, premium and Additional Interest, if any, on the Notes will be promptly paid
in full when due, whether at maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of and interest on the Notes, if any, if lawful, and all other obligations of the Issuer to the Holders or the Trustee hereunder
or thereunder will be promptly paid in full or performed, all in accordance with the terms hereof and thereof; and 

 (ii) in case of any extension of time of payment or renewal of any Notes or
any of such other obligations, that same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or otherwise. Failing payment when due of any amount
so guaranteed or any performance so guaranteed for whatever reason, the Guarantors and the Guaranteeing Subsidiary shall be jointly and severally obligated to pay the same immediately. This is a guarantee of payment and not a guarantee of
collection. 
 (b) The obligations hereunder shall be unconditional, irrespective of the validity, regularity or
enforceability of the Notes or the Indenture, the absence of any action to enforce the same, any waiver or consent by any Holder of the Notes with respect to any provisions hereof or thereof, the recovery of any judgment against the Issuer, any
action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or defense of a guarantor. 

(c) The following is hereby waived: diligence, presentment, demand of payment, filing of claims with a court in the event
of insolvency or bankruptcy of the Issuer, any right to require a proceeding first against the Issuer, protest, notice and all demands whatsoever. 

(d) This Guarantee shall not be discharged except by complete performance of the obligations contained in the Notes, the
Indenture and this Supplemental Indenture, and the Guaranteeing Subsidiary accepts all obligations of a Guarantor under the Indenture. 

(e) If any Holder or the Trustee is required by any court or otherwise to return to the Issuer, the Guarantors (including
the Guaranteeing Subsidiary), or any custodian, trustee, liquidator or other similar official acting in relation to either the Issuer or the Guarantors, any amount paid either to the Trustee or such Holder, this Guarantee, to the extent theretofore
discharged, shall be reinstated in full force and effect. 
 (f) The Guaranteeing Subsidiary shall not be
entitled to any right of subrogation in relation to the Holders in respect of any obligations guaranteed hereby until payment in full of all obligations guaranteed hereby. 

(g) As between the Guaranteeing Subsidiary, on the one hand, and the Holders and the Trustee, on the other hand,
(x) the maturity of the obligations guaranteed hereby may be accelerated as provided in Article 6 of the Indenture for the purposes of this Guarantee, notwithstanding any stay, injunction or other prohibition preventing such acceleration in
respect of the obligations guaranteed hereby, and (y) in the event of any declaration of acceleration of such obligations as provided in Article 6 of the Indenture, such obligations (whether or not due and payable) shall forthwith become due
and payable by the Guaranteeing Subsidiary for the purpose of this Guarantee. 
 (h) The Guaranteeing Subsidiary
shall have the right to seek contribution from any non-paying Guarantor so long as the exercise of such right does not impair the rights of the Holders under this Guarantee. 

(i) Pursuant to Section 11.02 of the Indenture, after giving effect to all other contingent and fixed liabilities
that are relevant under any applicable Bankruptcy or fraudulent conveyance laws, and after giving effect to any collections from, rights to receive contribution from or payments made by or on behalf of any other Guarantor in respect of the
obligations of such other Guarantor under Article 11 of the Indenture, this new Guarantee shall be limited to the maximum amount permissible such that the obligations of the Guaranteeing Subsidiary under this Guarantee will not constitute a
fraudulent transfer or conveyance. 
  

 2 

 (j) This Guarantee shall remain in full force and effect and continue to be
effective should any petition be filed by or against the Issuer for liquidation or reorganization, should the Issuer become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any
significant part of the Issuer’s assets, and shall, to the fullest extent permitted by law, continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Notes are, pursuant to applicable law,
rescinded or reduced in amount, or must otherwise be restored or returned by any obligee on the Notes and Guarantee, whether as a “voidable preference”, “fraudulent transfer” or otherwise, all as though such payment or
performance had not been made. In the event that any payment or any part thereof, is rescinded, reduced, restored or returned, the Note shall, to the fullest extent permitted by law, be reinstated and deemed reduced only by such amount paid and not
so rescinded, reduced, restored or returned. 
 (k) In case any provision of this Guarantee shall be invalid,
illegal or unenforceable, the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

(l) This Guarantee shall be a general unsecured senior subordinated obligation of the Guaranteeing Subsidiary, ranking
pari passu with any other future Senior Indebtedness of the Guaranteeing Subsidiary, if any. 
 (m)
Each payment to be made by the Guaranteeing Subsidiary in respect of this Guarantee shall be made without set-off, counterclaim, reduction or diminution of any kind or nature. 

(3) Execution and Delivery. The Guaranteeing Subsidiary agrees that the Guarantee shall remain in full force and effect
notwithstanding the absence of the endorsement of any notation of such Guarantee on the Notes. 
 (4) Merger, Consolidation
or Sale of All or Substantially All Assets. 
 (a) Except as otherwise provided in Section 5.01(c) of the Indenture,
the Guaranteeing Subsidiary may not consolidate or merge with or into or wind up into (whether or not the Issuer or the Guaranteeing Subsidiary is the surviving corporation), or sell, assign, transfer, lease, convey or otherwise dispose of all or
substantially all of its properties or assets, in one or more related transactions, to any Person unless: 
 (i)
(A) the Guaranteeing Subsidiary is the surviving corporation or the Person formed by or surviving any such consolidation or merger (if other than the Guaranteeing Subsidiary) or to which such sale, assignment, transfer, lease, conveyance or
other disposition will have been made is a corporation organized or existing under the laws of the jurisdiction of organization of the Guaranteeing Subsidiary, as the case may be, or the laws of the United States, any state thereof, the District of
Columbia, or any territory thereof (the Guaranteeing Subsidiary or such Person, as the case may be, being herein called the “Successor Person”); 

(B) the Successor Person, if other than the Guaranteeing Subsidiary, expressly assumes all the obligations of the
Guaranteeing Subsidiary under the Indenture and the Guaranteeing Subsidiary’s related Guarantee pursuant to supplemental indentures or other documents or instruments in form reasonably satisfactory to the Trustee; 

(C) immediately after such transaction, no Default exists; and 

 

 3 

 (D) the Issuer shall have delivered to the Trustee an Officer’s
Certificate and an Opinion of Counsel, each stating that such consolidation, merger or transfer and such supplemental indentures, if any, comply with the Indenture; or 

(ii) the transaction is made in compliance with Sections 4.10(a)(1) and (2) of the Indenture; 

(b) Subject to certain limitations described in the Indenture, the Successor Person will succeed to, and be substituted for, the
Guaranteeing Subsidiary under the Indenture and the Guaranteeing Subsidiary’s Guarantee. Notwithstanding the foregoing, the Guaranteeing Subsidiary may (x) consolidate or merge into or transfer all or part of its properties and assets to
another Guarantor or the Issuer or (y) merge with an Affiliate of the Issuer solely for the purpose of reincorporating the Guaranteeing Subsidiary in a State of the United States as long as the amount of the Indebtedness, Preferred Stock and
Disqualified Stock is not increased thereby. 
 (5) Releases. 

The Guarantee of the Guaranteeing Subsidiary shall be automatically and unconditionally released and discharged, and no further action by
the Guaranteeing Subsidiary, the Issuer or the Trustee is required for the release of the Guaranteeing Subsidiary’s Guarantee, upon: 

(1) (A) any sale, exchange or transfer (by merger or otherwise) of the Capital Stock of the Guaranteeing Subsidiary
(including any sale, exchange or transfer), after which the Guaranteeing Subsidiary is no longer a Restricted Subsidiary or all or substantially all the assets of the Guaranteeing Subsidiary which sale, exchange or transfer is made in compliance
with Sections 4.10(a)(1) and (2) of the Indenture; 
 (B) the release or discharge of the guarantee by the
Guaranteeing Subsidiary of the Senior Credit Facilities (including by reason of the termination of the Senior Credit Facilities) or the guarantee which resulted in the creation of the Guarantee, except a discharge or release by or as a result of
payment under such guarantee; 
 (C) the proper designation of the Guaranteeing Subsidiary as an Unrestricted
Subsidiary; or 
 (D) the Issuer exercising its Legal Defeasance option or Covenant Defeasance option in
accordance with Article 8 of the Indenture or the Issuer’s obligations under the Indenture being discharged in accordance with the terms of the Indenture; and 

(2) the Guaranteeing Subsidiary delivering to the Trustee an Officer’s Certificate and an Opinion of Counsel, each
stating that all conditions precedent provided for in the Indenture relating to such transaction have been complied with. 
 (6)
No Recourse Against Others. No director, officer, employee, incorporator or stockholder of the Guaranteeing Subsidiary shall have any liability for any obligations of the Issuer or the Guarantors (including the Guaranteeing Subsidiary) under
the Notes, any Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder by accepting Notes waives and releases all such liability. The waiver
and release are part of the consideration for issuance of the Notes. 
  

 4 

 (7) Governing Law. THIS SUPPLEMENTAL INDENTURE WILL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 
 (8) Counterparts. The parties may sign any number of copies of this
Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 (9)
Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof. 

(10) The Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency
of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary. 

(11) Subrogation. The Guaranteeing Subsidiary shall be subrogated to all rights of Holders of Notes against the Issuer in respect
of any amounts paid by the Guaranteeing Subsidiary pursuant to the provisions of Section 2 hereof and Section 11.01 of the Indenture; provided that, if an Event of Default has occurred and is continuing, the Guaranteeing Subsidiary
shall not be entitled to enforce or receive any payments arising out of, or based upon, such right of subrogation until all amounts then due and payable by the Issuer under the Indenture or the Notes shall have been paid in full. 

(12) Benefits Acknowledged. The Guaranteeing Subsidiary’s Guarantee is subject to the terms and conditions set forth in the
Indenture. The Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it
pursuant to this Guarantee are knowingly made in contemplation of such benefits. 
 (13) Successors. All agreements of
the Guaranteeing Subsidiary in this Supplemental Indenture shall bind its Successors, except as otherwise provided in Section 2(k) hereof or elsewhere in this Supplemental Indenture. All agreements of the Trustee in this Supplemental Indenture
shall bind its successors. 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed, all as of the date first above written. 
  

			
	WEST UNIFIED COMMUNICATIONS SERVICES, LLC
	
	BY: WEST CORPORATION, ITS SOLE MEMBER
		
	By:	 	 /s/ Paul M. Mendlik

	Name:	 	Paul M. Mendlik
	Title:	 	Chief Financial Officer/Treasurer

			
	 THE BANK OF NEW YORK MELLON TRUST

COMPANY, N.A., as Trustee

		
	By:	 	 /s/ Sharon McGrath

	Name:	 	Sharon McGrath
	Title:	 	Vice President

			
	Acknowledged and Agreed to by:
	
	WEST CORPORATION
		
	By:	 	 /s/ Paul M. Mendlik

	Name:	 	Paul M. Mendlik
	Title:	 	Chief Financial Officer/TreasurerFifth Amendment to the Amended and Restated Strategic Alliance Agreement

 Exhibit 10.18.4 

EXECUTION COPY 

FIFTH AMENDMENT TO THE AMENDED AND RESTATED STRATEGIC 

ALLIANCE AGREEMENT 

This Fifth Amendment to the Amended and Restated Strategic Alliance Agreement (this “Amendment”) dated as of June 8, 2010
is made by and between PENWEST PHARMACEUTICALS CO., a corporation organized and existing under the laws of the State of Washington, with its principal place of business at 2981 Route 22, Patterson, New York 12563 (“Penwest”), and ENDO
PHARMACEUTICALS INC., a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317 (“Endo”), and amends the Amended and Restated
Strategic Alliance Agreement, dated April 2, 2002, between Penwest and Endo (as amended, the “Strategic Alliance Agreement”). Any capitalized terms used but not defined in this Amendment will have the meaning ascribed to such terms in
the Strategic Alliance Agreement. Penwest and Endo are referred to in this Amendment as the “Parties” and individually as a “Party”. Any capitalized terms used but not defined herein will have the meaning ascribed to such terms
in the Strategic Alliance Agreement. 
 In consideration of the mutual covenants and conditions herein set forth, the receipt
and sufficiency of which consideration is hereby acknowledged, the Parties agree as follows: 
  

	1.	AMENDMENT TO ROYALTIES 

1.1 Effective April 1, 2010 and continuing through December 31, 2012 (the “First Royalty Reduction Period”), the
Royalty rate set forth in Section 4.5.1 of the Strategic Alliance Agreement with respect to the Product shall not exceed 22% as a percentage of U.S. Product Net Sales during such period, subject to the following sentences. During the fourth
calendar quarter of 2012, Penwest and Endo shall calculate the difference between the amount of Royalties for Product that would have been payable by Endo to Penwest during the First Royalty Reduction Period through the third calendar quarter of
2012 as if the Royalty rate had not been capped at 22% as provided in the first sentence of this paragraph and the amount of Royalties payable during such period giving effect to the 22% cap on the Royalty rate as provided in this paragraph. The
Royalty rate on U.S. Product Net Sales shall be adjusted during the fourth calendar quarter of 2012 to such percentage of U.S. Product Net Sales for Product for such calendar quarter as will result in the Royalties payable by Endo to Penwest in
respect to U.S. Product Net Sales for Product to be $7,300,000 lower for the First Royalty Reduction Period than the aggregate Royalties would have been for Product for such period had the Royalty rate not been adjusted for such period as provided
in this paragraph; provided, however, that Penwest shall have no obligation to make any payment to Endo as a result of the adjustments in this paragraph. 

1.2 Effective January 1, 2013 and continuing through December 31, 2013 (the “Second Royalty Reduction Period”), the
Royalty rate set forth in Section 4.5.1 of the Strategic Alliance Agreement with respect to the Product shall not exceed 20% as a percentage of U.S. Product Net Sales during such period, subject to the following sentences. During the fourth

  

 -1- 

 
calendar quarter of 2013, Penwest and Endo shall calculate the difference between the amount of Royalties for Product that would have been payable by Endo to Penwest for the Second Royalty
Reduction Period through the third calendar quarter of 2013 as if the Royalty rate had not been capped at 20% as provided in the first sentence of this paragraph and the amount of Royalties payable during such period giving effect to the 20% cap on
the Royalty rate as provided in this paragraph. The Royalty rate on U.S. Product Net Sales shall be adjusted for the fourth calendar quarter of 2013 to such percentage of U.S. Product Net Sales for Product during such period as will result in the
aggregate Royalties payable by Endo to Penwest in respect to U.S. Product Net Sales for Product to be $700,000 lower for the Second Royalty Reduction Period than the aggregate Royalties would have been for Product for such period had the Royalty
rate not been adjusted for such period as provided in this paragraph; provided, however, that Penwest shall have no obligation to make any payment to Endo as a result of the adjustments in this paragraph. 

1.3 Notwithstanding any other provision to the contrary, the Parties agree that sales of those Impax Products (as defined in the
Settlement Agreement) which are covered only by the Existing Patents (as defined in the Settlement Agreement) and sold during the applicable Exclusivity Period (as defined in the Settlement Agreement) shall not be considered sales of Licensed
Oxymorphone Products and no financial consideration, including, without limitation, royalties or sales milestones, shall be due to Penwest with respect to such sales. For all other Impax Product sales, any payments received by Endo from Impax with
respect to such sales shall be deemed to be “Applicable Sublicense Consideration” and Penwest shall be entitled to payment thereon pursuant to the Agreement. Penwest shall not be entitled to payment of any kind with respect to the sale of
any Licensed Oxymorphone Products for which Endo receives no consideration. “Settlement Agreement” means the Settlement and License Agreement entered into among Penwest, Endo and Impax Laboratories, Inc. (“Impax”) concurrently
herewith. 
 1.4 The Parties agree that Endo shall be solely responsible for all payments to Impax pursuant to the Settlement
Agreement and that Endo may not deduct such payments from Net Sales or offset such payments against any amounts owed by Endo to Penwest pursuant to the Strategic Alliance Agreement. 

 

	2.	MISCELLANEOUS 

 2.1
Except as set forth herein, no other portion of the Strategic Alliance Agreement is hereby amended and the terms of the Strategic Alliance Agreement shall continue in full force and effect. All references in the Strategic Alliance Agreement to
“this Agreement” shall be deemed to include the provisions of this Amendment. 
 2.2 This Amendment, together with the
Strategic Alliance Agreement, constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral between the Parties with respect to the subject matter hereof. 

2.3 Any terms of this Amendment may be amended, modified or waived only in a writing signed by both Parties. 

2.4 This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of New York without regard
to its conflict of laws rules. 
  

 -2- 

 2.5 Neither Party shall issue any press release or make any public announcements regarding
the subject matter of this Amendment and related provisions of the Strategic Alliance Agreement, as amended hereby, without the prior written consent of the other Party, which will not be unreasonably withheld; provided, however, that
notwithstanding the foregoing, either Party shall have the right to issue press releases and to make public announcements regarding the subject matter of this Amendment and related provisions of the Strategic Alliance Agreement, as amended hereby,
without the consent of the other Party in order to comply with disclosure obligations that are imposed by applicable law, regulation or legal process, including without limitation by rules and regulations under applicable securities laws and by
rules and regulations of any stock exchange or NASDAQ, provided that the Party complying with any such disclosure requirement shall, if practicable, provide the other Party with an opportunity to review and comment on the content of
any such disclosure, to the extent such content has not previously been disclosed publicly. 
 [Remainder of Page
Intentionally Left Blank] 
  

 -3- 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the date first above written. 

 

			
	ENDO PHARMACEUTICALS INC.

			
		
	By:	 	 /S/ DAVID P.
HOLVECK

  

			
	Name and Title:	 	 President and CEO

 

			
	Date:	 	 June 7, 2010

	
	PENWEST PHARMACEUTICALS CO.

			
		
	By:	 	 /S/ JENNIFER L.
GOOD

  

			
	Name and Title:	 	 President and CEO

 

			
	Date:	 	 June 7, 2010

 

 -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]